Not a healthcare professional? Go to the patient or caregiver website.

VYNDAQEL® OR VYNDAMAX™ Drug Interactions (tafamidis meglumine or tafamidis)

7. DRUG INTERACTIONS

7.1 BCRP Substrates

Tafamidis inhibits breast cancer resistant protein (BCRP) in vitro and may increase exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) following VYNDAQEL 80 mg or VYNDAMAX 61 mg. Dose adjustment may be needed for these substrates.

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No